Finerenone May Protect Against Pneumonia and COVID-19
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.
Diagnosis & Disease Information
Can SGLT2 and GLP1 Agents Be Cost-Effective First-Line Treatments for Diabetes?
Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.
NIH Study Compares Four Commonly Used Type 2 Diabetes Medications
The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.
SGLT-2 Inhibitors Show Benefit in Heart Failure With Preserved Ejection Fraction
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
Noninferiority of Once-Weekly Insulin Icodec Demonstrated in Two T2D Trials
The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.
Sotagliflozin Under Review for Heart Failure Treatment
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Fasting Blood Glucose Linked to Mortality Outcomes in Patients With COVID-19
Researchers assessed the relationship between fasting blood glucose levels and the risk of mortality in patients hospitalized with COVID-19.
Insulin Biosimilar Recalled Due to Missing Label on Prefilled Pens
The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn).
FDA Extends Review Period for Teplizumab for Type 1 Diabetes Delay
Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.
Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.
- Loading...
Loading...
Next post in Ophthalmology
Loading... 
Loading...